Metraipolis › archive › dc_8cee6f4fbf36
PCSK9 inhibitors improve lipid profile and hepatic steatosis surrogate indicators in patients with MAFLD and type 2 diabetes — Europe PMC PMID:41868208
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41868208
- DOI
- 10.3389/fmed.2026.1756998
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-05T03:31:44.178Z
- SHA-256 of the archived text
e38e24d11b1f71815c348f35bbcc87162390f43387d2cdc4dff6f94eeb48be55- Stable URL of this page
https://metraipolis.com/documento/dc_8cee6f4fbf36
How to cite
PCSK9 inhibitors improve lipid profile and hepatic steatosis surrogate indicators in patients with MAFLD and type 2 diabetes — Europe PMC PMID:41868208 — Europe PMC (en), https://europepmc.org/article/MED/41868208 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_8cee6f4fbf36 (Metraipolis archive dc_8cee6f4fbf36, sha256 e38e24d11b1f71815c348f35bbcc87162390f43387d2cdc4dff6f94eeb48be55)
BibTeX
@misc{dc8cee6f4fbf36,
title = {PCSK9 inhibitors improve lipid profile and hepatic steatosis surrogate indicators in patients with MAFLD and type 2 diabetes — Europe PMC PMID:41868208},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41868208},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_8cee6f4fbf36; sha256 e38e24d11b1f71815c348f35bbcc87162390f43387d2cdc4dff6f94eeb48be55},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41868208. Agents can read the archived copy with the MCP tool read_document.